Histidine decarboxylase (HDC), the unique enzyme responsible for histamine generation, is highly expressed in myeloid cells, but its function in these cells is poorly understood. Here we show that Hdc-knockout mice show a high rate of colon and skin carcinogenesis. Using Hdc-EGFP bacterial artificial chromosome (BAC) transgenic mice in which EGFP expression is controlled by the Hdc promoter, we show that Hdc is expressed primarily in CD11b + Ly6G + immature myeloid cells (IMCs) that are recruited early on in chemical carcinogenesis. Transplant of Hdc-deficient bone marrow to wild-type recipients results in increased CD11b + Ly6G + cell mobilization and reproduces the cancer susceptibility phenotype of Hdc-knockout mice. In addition, Hdcdeficient IMCs promote the growth of tumor allografts, whereas mouse CT26 colon cancer cells downregulate Hdc expression through promoter hypermethylation and inhibit myeloid cell maturation. Exogenous histamine induces the differentiation of IMCs and suppresses their ability to support the growth of tumor allografts. These data indicate key roles for Hdc and histamine in myeloid cell differentiation and CD11b + Ly6G + IMCs in early cancer development.
Accumulating evidence suggests that myeloid cells are a major component of tumor masses and are pivotal in promoting tumor progression 1-4 . In the bone marrow, CD11b + Gr-1 + IMCs are thought to represent myeloid precursor cells 5 . However, the myeloid lineage includes both monocytic cells, such as tumor-associated macrophages 4 , and granulocytic cells. It is also increasingly recognized that tumorigenesis in mice is associated with the recruitment of CD11b + Ly6G + tumor-associated neutrophils (TANs) that consist of two polarized phenotypes: N1 TANs that have hypersegmented or lobulated nuclei and are cytotoxic to tumor cells and N2 TANs that show circular or ovoid nuclei similar to immature neutrophils of bone marrow and that are protumorigenic 6, 7 . N2 TANs support tumor growth by producing nitric oxide, angiogenic factors and matrix-degrading enzymes 8 . Transforming growth factor-β (TGF-β) seems to promote N2 polarization 6 , and these cells then contribute to suppression of antitumor immune responses 9 and promotion of metastatic behavior 10 .
Most TANs are CD11b + Ly6G + and thus are classified as a subset of CD11b + Gr-1 + cells, which also include myeloid-derived suppressor cells (MDSCs), a heterogeneous population of myeloid cells in mice that are excessively produced in cancer. MDSCs can be detected in the circulation in people with cancer and accumulate in larger numbers in the spleen of cancer-bearing mice [11] [12] [13] . MDSCs include both monocytic (Ly6G − Ly6C high ) and granulocytic (Ly6G + Ly6C low ) cells 14 , with the latter sharing cell surface markers similar to TANs. However, MDSCs are defined functionally by their ability to suppress T cell responses 15 , and recent studies have suggested that the functional MDSCs are CD11b + CD49d + and monocytic (CD11b + Ly6C + ), unlike TANs, which are granulocytic (CD11b + Ly6G + ) and poorly inhibit T cell proliferation 16 . CD11b + Gr-1 + IMCs can be detected in the bone marrow and occasionally in the spleen of cancer-free mice 11 , raising a number of questions regarding the origins of TANs and MDSCs and the role of IMCs in early stages of tumorigenesis 6, 14 .
Histamine is a biogenic amine that has well defined roles in allergic responses and gastric acid secretion and has also been linked to the modulation of immune responses. For example, histamine has been shown to regulate T cells, enhancing T helper type 1 (T H 1) responses through the H 1 receptor and downregulating both T H 1 and T H 2 responses through the H 2 receptor 17 . Furthermore, histamine is believed to have an immune regulatory function in myeloid cells [18] [19] [20] . Histamine can be taken up in the diet, but endogenous histamine is generated through conversion of L-histidine to histamine by the action of a unique enzyme, HDC. Although mast cells are known to store histamine, recent studies have suggested that other types of myeloid cells may be key sources of histamine production 21, 22 . In mouse models of atherosclerosis, Hdc-expressing myeloid cells are primarily bone marrow derived and appear more like monocytic precursors rather than mature macrophages 23 . Knockout of the Hdc gene has been reported [24] [25] [26] , but little is known regarding the role of histamine in carcinogenesis. Although individuals with atopic allergy and excessive histamine release are reported to have a reduced incidence of cancer, the mechanisms remain unclear 27, 28 . Here we report that Hdc is primarily expressed in CD11b + Ly6G + IMCs within the bone marrow where histamine promotes myeloid cell differentiation leading to suppression of cancer formation.
RESULTS
Hdc −/− mice are susceptible to colon and skin carcinogenesis We injected histamine-deficient Hdc −/− and wild-type mice intraperitoneally with one dose of a genotoxic colonic carcinogen, azoxymethane (AOM), followed by 10 d of oral exposure to a nongenotoxic carcinogen, dextran sodium sulfate (DSS) 29 . Although both sets of mice developed colonic tumors, Hdc −/− mice showed significantly greater colorectal tumor number and size compared to wild-type mice 15 weeks after DSS treatment ( Fig. 1a,b) . Whereas wild-type mice had low-grade dysplasia and tubular adenoma with scattered goblet cells, Hdc −/− mice showed high-grade dysplasia, intramucosal carcinoma and invasive adenocarcinoma with rare goblet cells ( Fig. 1c and Supplementary Fig. 1a ), along with a greater degree of inflammatory infiltrate and a significant increase of proinflammatory cytokines interleukin-1α (IL-1α), IL-1β and IL-6 mRNA expression in the colon tumors (P < 0.05) ( Supplementary Fig. 1b,c) . Tumors from the Hdc −/− mice showed abundant nuclear staining for β-catenin, which was less often present in tumors from wild-type mice (Supplementary Fig. 1f ).
To extend these observations, we used the two-stage inflammation-associated skin carcinogenesis protocol using 9,10-dimethyl-1, 2-benzanthracene (DMBA) and 12-O-tetradecanoylpherorbol 13-acetate (TPA). Hdc −/− mice first developed microscopic skin papillomas 10 weeks after TPA promotion, followed by macroscopic skin tumors 4 months later. The number and size of the skin tumors in Hdc −/− mice were markedly greater than in wild-type mice ( Fig. 1d,e ). While most lesions were predominantly composed of benign papillomas, some of the skin tumors in Hdc −/− mice progressed to cancer ( Fig. 1f) , and there was a greater number of infiltrating inflammatory cells and increased expression of the proinflammatory cytokines IL-1α and IL-6 mRNA expression in the skin tumors of Hdc −/− mice ( Supplementary Fig. 1d,e ). Taken together, these carcinogenesis studies suggest that Hdc and histamine may be protective in inflammation-associated cancer.
Hdc is expressed mostly in CD11b + Ly6G + immature myeloid cells To determine the source of Hdc responsible for the protection against cancer, we generated an Hdc-EGFP BAC-transgenic reporter mouse with a previously published EGFP-containing cassette 30 ( Supplementary Fig. 2a ). We observed EGFP fluorescence in a variety of adult tissues, consistent with previous reports of endogenous Hdc expression [31] [32] [33] . In the gastrointestinal tract, EGFP fluorescence was detectable in enteroendocrine cells at the base of the gastric oxyntic glands, whereas rare EGFP + enteroendocrine cells were apparent in the small intestine and colon, confirmed by staining for E-cadherin and chromogranin A ( Supplementary Fig. 3a) . We observed scattered EGFP + cells in the dermis of the skin and connective tissue layer of the lung, and numerous EGFP + cells were distributed in the red pulp of the spleen (Supplementary Fig. 2b ). Consistent with earlier literature, we found strong EGFP fluorescence in the ventral hypothalamus ( Supplementary Fig. 2b) .
Although for many years mast cells were postulated to be the major histamine-releasing cells in the intestine and other organs, immunostaining for tryptase confirmed that the majority of EGFP + cells in the intestine, peritoneum and bone marrow were not mast cells ( Supplementary Fig. 3c-f ). Immunostaining also confirmed that the vast majority of c-Kit + mast cells in the dermis of TPA-treated Hdc-EGFP mice, and in the colonic tumor stroma of Hdc-EGFP mice treated with AOM and DSS, showed no colocalization with EGFP + cells ( Supplementary Fig. 3g,h) . Furthermore, FACS analysis showed little expression of Hdc-EGFP in c-kit + FcεR + mast cells of the spleen and peritoneum and IL-3-dependent bone marrow-derived mast cells ( Supplementary Fig. 4a,b) . Instead, the most robust site of EGFP expression was found in bone marrow cells. FACS analysis revealed that 30-40% of bone marrow cells were EGFP + and thus expressing Hdc (Fig. 2a) . Staining with antibody to Hdc and RT-PCR analysis confirmed Hdc expression in EGFP + cells, whereas we did not detect Hdc expression in EGFP − cells ( Supplementary Fig. 5a,b) . Further FACS analysis showed that the vast majority of EGFP + cells were of myeloid lineages, as nearly all of the cells expressed granulocyte markers Gr-1 (~87%) and Ly6G and myeloid cell marker CD11b (~90%), whereas they were generally negative for CD3, CD19, CD34 and Flk-1 ( Supplementary Fig. 5c and Fig. 2b ). FACS data also indicated that EGFP + cells in the peritoneum were CD11b + myeloid cells, rather than c-kit + FcεR + mast cells ( Fig. 2c) . Taken together, these data suggest that CD11b + Gr-1 + IMCs are the major source of Hdc expression within the bone marrow.
CD11b + Gr-1 + IMCs comprise both the Ly6G + granulocytic and Ly6C + monocytic subsets. With an antibody to Ly6G, we found that EGFP is predominately expressed in CD11b + Ly6G high cells (~60%) and of CD11b + Ly6G medium cells (~30%) as compared to the CD11b + Ly6Gsubset (~10%) ( Fig. 2b) . Thus, Hdc-EGFP is expressed primarily in the CD11b + Ly6G + myeloid subset that, by its cell surface markers, shows some similarity to CD11b + Ly6G + TANs 6 . In addition, we confirmed that Hdc-EGFP was mainly expressed in CD11b + CD49d − granulocytic cells in the bone marrow, spleen and peripheral blood ( Supplementary Fig. 6a-c) . Notably, we found EGFP expression was markedly decreased in differentiated granulocytes (neutrophils) derived from EGFP + CD11b + Ly6G + cells treated with granulocyte colonystimulating factor (G-CSF) ( Fig. 2d) . Similarly, incubation of either EGFP + or EGFP − CD11b + Gr-1 + IMCs with granulocyte-macrophage colony-stimulating factor (GM-CSF) resulted in differentiation into monocytes, and in the EGFP + IMCs this resulted in repression of EGFP expression ( Supplementary Fig. 7a ). Real-time RT-PCR results confirmed that Hdc expression was significantly decreased in the differentiated monocytes and macrophages (P < 0.01) ( Supplementary Fig. 7b ). Taken together, the Hdc-EGFP + myeloid lineage seems to comprise precursor cells for both the monocytic and granulocytic lineages, and expression of Hdc is suppressed during in vitro differentiation.
Histamine regulates the differentiation of CD11b + Gr-1 + IMCs
The expression of Hdc in IMCs, but not in mature granulocytes and macrophages, suggested the possibility of a role for histamine in the differentiation of CD11b + Gr-1 + myeloid subsets. Consequently, we examined the effects on myeloid subsets of histamine in Hdc −/− mice ( Fig. 3a) and of the irreversible Hdc inhibitor α-fluoromethylhistidine in wild-type mice ( Supplementary Fig. 8a ). FACS analysis revealed that repression of Hdc function by these two approaches significantly increased (P < 0.05) the percentage of CD11b + Gr-1 + IMCs in the bone marrow, spleen and peripheral blood. Furthermore, the relative proportion of the CD11b + Ly6G + subset was markedly increased in the peripheral blood of Hdc −/− mice, in particular in Hdc −/− mice bearing colon tumors induced by AOM and DSS (Fig. 3b) . The increased proportion of granulocytic (CD11b + Ly6G + Ly6C − ) and CD11b + Ly6G + Ly6C + IMCs in the spleen and circulation of Hdc −/− mice, and the decreased proportion of CD11b + Ly6G − Ly6C + (Fig. 3c) , CD11b + Gr-1 − (Supplementary Fig. 9a -c) or CD11b + CD49d + (Supplementary Fig. 10a ) monocytic cells, suggested that histamine deficiency might inhibit the differentiation of monocytes. In addition, Hdc −/− mice also showed a reduced circulating level of mature neutrophils (CD11b − Gr-1 + ), suggesting that histamine deficiency might block the maturation of granulocytes ( Supplementary Fig. 9a,b,d) .
In contrast, complete blood counts of wild-type and Hdc −/− mice showed that numbers of neutrophils were increased, whereas monocytes showed no statistical change ( Supplementary Fig. 8b-d a r t i c l e s 9 0 VOLUME 17 | NUMBER 1 | JANUARY 2011 nature medicine monocytes is not able to distinguish between mature and immature myeloid cells, and the increase in neutrophils also reflects the increase in immature CD11b + Ly6G + cells.
To further characterize the effects of histamine, we isolated EGFP + IMCs from the bone marrow of Hdc-EGFP mice and analyzed them by FACS after incubating them with GM-CSF alone or with GM-CSF plus histamine. GM-CSF incubation induced both CD11b + Ly6G + granulocytic and CD11b + Ly6C + monocytic differentiation, and exogenous histamine promoted the differentiation of the CD11b + Ly6C + monocytic subset and decreased the proportion of the CD11b + Ly6G + granulocytic subset ( Fig. 3d) . To further address the hypothesis that histamine regulates the maturation of CD11b + Ly6G + granulocytes, we compared the morphologic appearance of splenic CD11b + Ly6G + granulocytes from Hdc −/− and wild-type mice. The nuclear morphology of CD11b + Ly6G + myeloid cells from Hdc −/− mice was characterized by an ovoid or circular nucleus, similar in some respects to N2 TANs 6 , whereas CD11b + Ly6G + cells from wild-type mice had hypersegmented nuclei typical of mature neutrophils (N1 phenotype) ( Supplementary Fig. 10b ).
Hdc deficiency leads to a marked reduction in histamine production and availability, and thus we postulated that within the bone marrow histamine acts in an autocrine or paracrine manner through defined histamine receptors. We examined histamine receptor expression in myeloid subsets within the bone marrow. Among the four histamine receptors (H 1 R-H 4 R), we identified H 1 R and H 2 R as the predominant receptors in CD11b + Gr-1 + IMCs, and H 1 R was highly expressed in CD11b + Ly6C + monocytic cells ( Supplementary  Fig. 10c ). Staining with antibodies to H 1 R or H 2 R confirmed H 1 R and H 2 R protein expression in CD11b + Ly6G + and CD11b + Ly6C + IMCs and also revealed increased H 1 R and H 2 R expression in weakly fluorescent EGFP + cells (Supplementary Fig. 10d ). In addition, H 1 R and H 2 R antagonists were both effective (although H 1 R more so) in inhibiting the monocytic differentiation of CD11b + Ly6C + cells from IMCs after histamine plus GM-CSF treatment (Fig. 3e) . Finally, administration of exogenous histamine in Hdc −/− mice significantly decreased circulating CD11b + Gr-1 + IMCs (P < 0.05) ( Fig. 3f) . Taken together, these results suggest that histamine promotes the differentiation of CD11b + Gr-1 + IMCs and CD11b + Ly6C + monocytes through H 1 R and H 2 R autocrine and paracrine pathways.
Hdc + IMCs are activated and recruited to colon tumors To show that Hdc + myeloid cells are recruited by carcinogenic stimuli, we examined EGFP expression in the AOM plus DSS mouse model of colon cancer. Twenty weeks after AOM and DSS treatment, at a time when gross colonic tumors could be observed in most (80%) Hdc-EGFP mice, there was marked infiltration of EGFP + cells in the colonic adenomas compared to only rare submucosal EGFP + cells in the colons of control mice ( Fig. 4a and data not shown). In the mice treated with AOM and DSS, we confirmed the presence of numerous CD11b + Gr-1 + myeloid cells in the stroma of tumors ( Fig. 4a) . Of note, at earlier time points (10 d and 8 weeks) after AOM and DSS treatment but before tumor development (20 weeks), there was an even greater number of Hdc-EGFP + myeloid cells infiltrating the inflamed colon tissue (Fig. 4b,c) . Thus, there is a strong correlation between the early recruitment of EGFP + IMCs and tumor development. Consistent with this notion, one or two doses of AOM resulted in no substantial recruitment of EGFP + cells to the colon and also no induction of cancer (data not shown), suggesting that the tumor promoter DSS might in part induce cancer through IMC recruitment. Indeed, DSS treatment resulted in significant mobilization of CD11b + Gr-1 + IMCs in the peripheral blood within 4 d, with minimal changes in CD11b + Gr-1 − monocytes or CD11b − Gr-1 + granulocytes (P < 0.01) ( Supplementary Fig. 11a ). Furthermore, EGFP + cells in the inflamed colon mucosa were positive for CD11b-and Gr-1-specific antibody staining (Supplementary Fig. 11b ).
To determine whether HDC + myeloid cells are also present in human colon cancer, we carried out an immunohistochemical study of human ulcerative colitis (preneoplastic lesion) and colitisassociated colorectal cancer of different subjects. Similar to our mouse models ( Fig. 4a and Supplementary Fig. 11c ), human ulcerative colitis was characterized by a marked infiltration of HDC + cells that were largely restricted to CD11b + cells. Furthermore, in colorectal cancer, CD11b + cells were still extremely abundant in areas adjacent to the tumor but showed marked downregulation of HDC and an immature morphology within the tumor ( Fig. 4d and Supplementary  Fig. 11d) . Consistent with the observation from mouse colon tumors (Supplementary Fig. 3h) , HDC + inflammatory cells in human colorectal cancer are not tryptase-positive mast cells (Fig. 4d) .
It has previously been reported that a single application of TPA results in rapid recruitment of Gr-1 + inflammatory cells and increased Hdc activity in the skin 34, 35 . After TPA treatment, a substantial number of Hdc-EGFP + cells were recruited to the dermis and subcutaneous tissue, with a much greater number at 24 h compared to 6 h after treatment (Fig. 4e) . FACS analysis of circulating cells in the peripheral blood confirmed that the percentage of CD11b + Gr-1 + cells is increased by ~3.5 fold 1 d after a single TPA application (data not shown). More than half of the CD45 + cells in the TPA-treated dermis expressed EGFP, and the vast majority of EGFP + cells expressed Gr-1 or CD11b (Supplementary Fig. 12a,b ) but did not express tryptase (Supplementary Fig. 12c ) and c-kit (Supplementary Fig. 3g ). In addition, bone marrow transplant experiments showed that the EGFP + cells that infiltrated the colon (Fig. 4c) and dermis of skin ( Supplementary Fig. 12d ) were bone marrow derived.
We next examined gene expression patterns of bone marrow-derived CD11b + Gr-1 + IMCs and colon tumor-associated CD11b + Gr-1 + MDSCs from wild-type and Hdc −/− mice using a mouse array directly after FACS sorting. These studies revealed that, at baseline, Hdc −/− bone marrow-derived IMCs showed increased inflammatory cytokine (that is, IL-1) and chemokine (that is, CCR2) expression compared to wild-type IMCs. Notably, we found that tumor-associated MDSCs from both wild-type and Hdc −/− mice showed a much greater (fivefold) increase in the expression of IL-1 family ligands (IL-1α, IL-1β and IL-18) and IL-6 ( Supplementary Table 1 ), along with overexpression of a number of chemokines and chemokine receptors, including CXCL1, CXCL2 and CCR2 (Supplementary Table 2) , and adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and CD44 (Supplementary Table 3) . BMT 
IMCs from Hdc −/− mice accelerate tumor growth
To confirm that loss of Hdc expression specifically in bone marrow cells promotes tumor growth, we studied wild-type mice reconstituted with either wild-type or Hdc −/− bone marrow. Mice transplanted with Hdc −/− bone marrow showed greater susceptibility to carcinogenesis in both the AOM plus DSS-induced colon carcinogenesis model (Fig. 5a ) and the DMBA plus TPA-induced skin carcinogenesis model (data not shown), at a level close to that found in Hdc −/− mice. Hdc −/− mice reconstituted with wild-type bone marrow showed reduced susceptibility to colon carcinogenesis compared with Hdc −/− mice (Fig. 5a) .
To show that Hdc-expressing CD11b + Gr-1 + or CD11b + Ly6G + IMCs contribute directly to tumor growth, we used an allograft tumor model in which mouse (CT26) colon cancer cells were injected subcutaneously into nonobese diabetic, severe combined immunodeficient (NOD-SCID) mice with bone marrow-derived IMCs isolated from wild-type or Hdc −/− mice 36 . CD11b + Gr-1 + IMCs from Hdc −/− mice promoted greater growth of the allograft tumors than did wildtype CD11b + Gr-1 + IMCs (Supplementary Fig. 13a ). We found that CD11b + Ly6G + IMCs from Hdc −/− mice more strongly promoted the growth of CT26 cancer cells compared to the IMCs of wild-type mice ( Fig. 5b and Supplementary Fig. 14) . Furthermore, we confirmed that bone marrow-derived Hdc-EGFP + CD11b + Gr-1 + IMCs can strongly promote the growth of CT26 cancer cells ( Supplementary  Fig. 13b ). To confirm that bone marrow-derived IMCs did not promote tumor growth as a result of immunosuppression, we incubated bone marrow-derived EGFP + CD11b + Gr-1 + IMCs with splenic CD4 + T cells. In contrast to splenic CD11b + Gr-1 + MDSCs that suppressed interferon-γ secretion from T cells, bone marrow-derived IMCs failed to have this effect (Supplementary Fig. 13c ). Taken together, these data indicate that bone marrow-derived CD11b + Gr-1 + and CD11b + Ly6G + IMCs can directly promote tumor proliferation independent of effects on T cells.
Indeed, the CD11b + Gr-1 + or CD11b + Ly6G + IMCs from Hdc −/− mice showed much higher expression of proinflammatory cytokines, including an eightfold increase in IL-6 ( Fig. 5c and Supplementary  Table 1 ), compared to those from wild-type mice. As previous studies have indicated a key role for IL-6 in colonic carcinogenesis 37, 38 , we examined CD11b + Ly6G + IMCs from the bone marrow of Il6 −/− mice.
Il6 deficiency resulted in significantly less stimulation of allograft tumor growth compared with wild-type CD11b + Ly6G + IMCs, indicating a major role for IL-6 in the promotion of tumor growth by IMCs (Fig. 5d) . In addition, allograft tumors that were implanted together with the EGFP + CD11b + Gr-1 + IMCs showed much greater neovascularization compared to the no-IMC implanted group ( Supplementary  Fig. 13b) , and the number of vessel branch points was significantly increased in allograft tumors implanted with CD11b + Ly6G + IMCs, an effect that was inhibited by deletion of the Il6 gene (P < 0.05) (Fig. 5e,f and Supplementary Fig. 14) . Finally, tumor cells implanted with EGFP + CD11b + Gr-1 + IMCs showed greater proliferation and recruitment of α-SMA + (α-smooth muscle actin) cancerassociated fibroblasts compared to the no-IMC implanted group (Fig. 6a) . Colonic adenomas from Hdc −/− mice also showed much greater α-SMA + stromal cells compared to wild-type mice (Fig. 6b) . Thus, these data suggest that CD11b + Gr-1 + or CD11b + Ly6G + IMCs promote the growth of tumors in part through IL-6 expression and modulation of the tumor microenvironment.
To further explore the mechanism of CD11b + Gr-1 + IMC migration and recruitment in inflamed tissue, we monitored circulating EGFP + CD11b + Gr-1 + IMCs in real time by intravital confocal microscopy. We examined the ears of Hdc-EGFP and Hdc-deficient Hdc-EGFP mice 6 h and 24 h after a single application of TPA. Six hours after TPA stimulation, we observed many EGFP + inflammatory cells in the dermis (Supplementary Fig. 15a ) and ear vessels (Supplementary Video 1) , compared to rare EGFP + cells in the circulation and tissue of control mice (data not shown).
The increased recruitment of IMCs in Hdc −/− mice could be related in part to the increased number of circulating cells or to increased migration in response to the incipient tumor site. Using immunofluorescence staining and FACS, we found that when the same number of bone marrow-derived EGFP + CD11b + Gr-1 + IMCs from Hdc-EGFP or Hdc-deficient Hdc-EGFP mice were injected by tail vein into CT26 colon tumor-bearing NOD-SCID mice, approximately three times more tumor-infiltrating EGFP + CD11b + cells, CD11b + Gr-1 + IMC, and F4/80 + macrophages from Hdc −/− mice versus from wild-type mice migrated to the tumor sites ( Supplementary Fig. 15b-d) . Recently, a number of ligands for RAGE (receptor for advanced glycation end production) have been implicated in monocyte and macrophage recruitment 39 . To examine the expression of RAGE ligands in DSSinduced colitis, we performed quantitative RT-PCR (qRT-PCR) and detected a significant increase in the expression of the RAGE ligand S100A8 in colitis tissue (P < 0.05) ( Fig. 6c ) and tumors (P < 0.05) ( Fig. 6d) . When we treated Rage −/− mice with AOM and DSS, we observed a significant reduction in circulating CD11b + Gr-1 + IMCs compared to wild-type mice (P < 0.01) (Fig. 6e) . These data suggest that Hdc deficiency increases the activation and recruitment of CD11b + Gr-1 + or CD11b + Ly6G + IMCs in response to carcinogenic stimuli and that bone marrow-derived IMCs constitute the majority of recruited EGFP + inflammatory cells in carcinogenesis. Given the downregulation of Hdc expression in colitis-associated cancer, we reasoned that cancer cells might be selectively modulating myeloid cells through repression of Hdc. First, we confirmed that when CD11b + Ly6G + or CD11b + Ly6C + IMCs isolated from Hdc-EGFP mice were cultured under differentiating conditions in vitro with CT26 colon cancer cells, there was greater downregulation of Hdc-EGFP expression ( Supplementary Fig. 16a,b) along with a less differentiated nuclear morphology (ovoid or circular nuclei) ( Supplementary Fig. 16c ) compared to the control group without CT26 cancer cells. This seemed to be cancer specific, as CT26 cells suppressed Hdc-EGFP expression in IMCs to a much greater extent compared to IEC-6 nontransformed intestinal epithelial cells ( Fig. 6f  and Supplementary Fig. 16d ). Furthermore, the addition of exogenous histamine to IMCs cultured in vitro with CT26 cells was able to promote the differentiation of these IMCs (Supplementary Fig. 16c ). We confirmed this through in vivo studies, where exogenous histamine given by intraperitoneal injection inhibited the promotion of allograft tumor growth by CD11b + Ly6G + IMCs from Hdc −/− mice (Fig. 5b) . We found that Hdc was also downregulated in our allograft models, by decreased EGFP expression in the Hdc-EGFP + CD11b + Gr-1 + IMCs 2 d after implantation with CT26 cancer cells in NOD-SCID mice (Supplementary Fig. 17) . In contrast, CD11b + Gr-1 + bone marrow-derived IMCs from UBC-EGFP mice (EGFP expression under the direction of the human ubiqutin C promoter, which can be examined in all tissues) did not show such loss of EGFP expression when implanted along with CT26 cancer cells (Supplementary Fig. 17 ). Previous reports have indicated that Hdc transcription is largely regulated by promoter CpG methylation 40, 41 , and we found increased DNA CpG methylation sites in the Hdc promoter region of Hdc-EGFP + CD11b + Ly6G + cells after a 48 h coculture with CT26 cells (Fig. 6g ). In addition, microarray studies indicated the upregulation of a number of DNA methylation genes (for example, Dnmt3a) in tumor-associated MDSCs compared to bone marrow-derived IMCs, supporting an induction of DNA methylation in IMCs by colonic tumors (Supplementary Table 4) . Overall, these data are consistent with the notion that cancer cells downregulate Hdc expression to prevent maturation of myeloid cells and thus promote tumor growth.
DISCUSSION
We show here that the Hdc gene is expressed primarily in bone marrow CD11b + Gr-1 + IMCs and that these IMCs contribute to the initiation and promotion of cancer. Histamine seems to be involved in the normal maturation and differentiation of myeloid cells, and a deficiency in Hdc leads to abnormal myeloid differentiation and the promotion of colonic and skin carcinogenesis. Cancers seem to locally mimic the Hdc-knockout phenotype by downregulating Hdc expression in nearby myeloid cells through the induction of Hdc promoter hypermethylation, thereby inhibiting further myeloid differentiation. The increased carcinogenesis observed in the Hdc −/− mouse was due primarily to Hdc deficiency in the bone marrow cells and was associated with increased recruitment of IMCs to the cancer sites in a RAGE-dependent manner 39 . The induction of cancer by IMCs was mediated through an Il6-dependent mechanism, as deletion of Il6 in the IMCs resulted in inhibition of tumor growth and angiogenesis. Previously, mast cells were considered the primary source of Hdc, as they are known to store and release histamine. However, our study shows that Hdc is not expressed by tryptase-positive or c-kit + FcεR + tissue mast cells but rather by CD11b + Gr-1 + IMCs that constitute 30-40% of bone marrow hematopoietic cells. Hdc expression was largely localized to the CD11b + Ly6G + granulocytic subset within the bone marrow, where it seemed to contribute to myeloid differentiation in an H 1 R-and H 2 R-dependent manner. Deletion or inhibition (via α-fluoromethylhistidine) of Hdc resulted in marked abnormalities in myeloid differentiation, fewer circulating mature granulocytes and monocytes and more CD11b + Ly6G + IMCs. Although these changes were not clearly reflected in automated (Coulter) counting of peripheral leukocytes, the changes were confirmed by both FACS and manual counting of peripheral smears (data not shown). Thus, Hdc + CD11b + Gr-1 + cells might function as precursors for both mature neutrophils and monocytes.
In both mouse and human studies, we observed that most CD11b + cells were also HDC + in preneoplastic tissues, whereas there was a much lower frequency of HDC + cells among CD11b + cells in established cancers. Hypermethylation of CpG promoter sites was associated with downregulation of Hdc expression in Hdc-EGFP + IMCs cultured with colon cancer cells, suggesting that this may be a tumor-induced phenomenon. Cancer cells seem to epigenetically reprogram myeloid progenitors, which might account for the development of TANs or even MDSCs in the setting of cancer. Indeed, our microarray data showed substantial differences in gene expression between bone marrow-derived Hdc + CD11b + Gr-1 + IMCs and tumor-associated MDSCs, including the upregulation of methylation genes associated with epigenetic reprogramming. Thus, whereas bone marrow-derived Hdc + CD11b + Gr-1 + IMCs (mainly expressing CD11b and Ly6G) superficially resemble MDSCs with respect to surface markers, they are CD11b + CD49d − and not able to suppress T cell function, and thus they are functionally distinct from MDSCs 16 and more closely resemble TANs.
In early stages of skin and colonic carcinogenesis, Hdc + IMCs are rapidly recruited to the sites of carcinogenic stimulus exposure, where they contribute to tumor development. We show here that tumorpromoting agents, such as TPA in the skin or DSS in the colon, work in large part by mobilizing and recruiting Hdc + IMCs. Increased cancer susceptibility in Hdc −/− mice was a general phenomenon mediated largely by Hdc deficiency in bone marrow cells. Although we could not completely exclude a role for non-bone marrow-derived Hdc in our transplants, the evidence for recipient Hdc was related to the incomplete (~70%) nature of the bone marrow transplants. The increased cancer susceptibility of Hdc −/− mice was due to an increase in circulating IMCs, as well as a RAGE-dependent, threefold greater migration and recruitment of Hdc −/− IMCs to the cancer site. Hdc −/− IMCs also expressed increased Il6 expression upon LPS stimulation, and knockout of Il6 in bone marrow IMCs reduced their ability to promote tumor growth and angiogenesis, consistent with previous studies 37, 38 . Our findings also point to a direct effect of IMCs on tumor promotion, as we found that, in the setting of histamine deficiency, exogenous histamine partially reversed the effects. Lack of complete reversal by exogenous histamine is consistent with previous findings that in immature mast cells exogenous histamine is unable to completely substitute for endogenous histamine 42 .
Growing evidence points to a major role for CD11b + Gr-1 + cells in cancer promotion. Although cancerous tissues have for many years been known to be histamine rich, our studies indicate that histamine is derived largely from Hdc + CD11b + Ly6G + IMCs. In previous studies, H 2 R antagonists have been shown to be generally ineffective in the treatment of cancer [43] [44] [45] ; this may have been, in part, a result of their inhibitory effects on the differentiation of IMCs. However, further studies are needed to assess the impact on cancer risk of histamine receptor antagonists, particularly H 1 R antagonists that have not been examined 46 . Notably, individuals with atopic disease, associated with increased histamine secretion, seem to be less susceptible to carcinogenesis compared with the general population 27, 28, 47, 48 . This has been attributed to enhanced immunosurveillance, but, given our findings, it could also be related to histamine-dependent effects on IMCs. Recently, a genetic mutation of HDC leading to loss of function has been described in association with Tourette's syndrome, however, the cancer susceptibility of this family has not been reported 26 . Overall, our results suggest that the balance of histamine within the tumor microenvironment may be crucial and that CD11b + Gr-1 + IMCs represent a key therapeutic target for the control of cancer growth.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
